BL-M07D1 (Trastuzumab Brengitecan T-bren) vs Standard of Care Platinum-based Chemotherapy (PBC) for HER2-expressing Metastatic Urothelial Cancer After Progression on Anti-PD-(L)1-based Therapy

The objective of the study is to evaluate the efficacy and safety of T-bren in participants with HER2 expressing metastatic UC with progression on or after anti-PD-(L)1-based therapy.

Trial Details

NCT ID
NCT07869836
Phase
PHASE3
Sponsor
SystImmune Inc.
Status
RECRUITING
Cancer Type
Bladder Cancer
Interventions
  • T-Bren, Dose level 1
  • T-bren, Dose level 2
  • Gemcitabine + Platinum Based Chemotherapy (Cisplatin or Carboplatin)
Locations (sample)
  • Macon, Georgia, United States|32.84069,-83.6324
  • ‘Aiea, Hawaii, United States|21.38222,-157.93361
  • Fredericksburg, Virginia, United States|38.30318,-77.46054

Key Eligibility Criteria

  • Histologically or cytologically documented metastatic or surgically unresectable transitional cell carcinoma (TCC) of the urothelium involving the …
  • Disease progression or recurrence during or following anti-PD-(L)1-based therapy.
  • Fresh biopsy or archival tumor samples.
  • Documented HER2 expression by central laboratory testing.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Bladder Cancer Trials on Trialify →